Consortium Member of the Month

Our consortium member of the month for the month of December goes to Zinedine Hoque from Mount Sinai Health System!

Zinedine Hoque

Zinedine has been an invaluable contributor to the Myeloproliferative Neoplasms Research Consortium, working closely with both Core B and Project 4. She consistently exceeded expectations in patient consenting for the MPN-RC 106 Tissue Bank and provided vital support to Project 4 through clinical trial coordination and regulatory tasks. In addition, she played a key role in managing biospecimen requests, including retrieving samples from the MPN-RC 106 Tissue Bank and facilitating their shipment to external researchers. Her commitment to supporting colleagues is equally noteworthy. Zinedine developed a comprehensive and user-friendly REDCap guide that has become an essential resource for newly hired Clinical Research Coordinators when entering patient data.

Although Zinedine transitioned out of her role in October 2025, we want to take this opportunity to recognize and appreciate her outstanding contributions. We are truly grateful for Zinedine’s dedication, professionalism, and exceptional work. Thank you for everything you’ve done!

Nominated by: Victoria Rivera

Zinedine, thank you so much for all of the phenomenal work you have done for the consortium.

Keep up the great work!

MPN/Leukemia Workshop

Date: November 14th, 2025

Thank you to all of those who attended and presented at the workshop!

ASH Conference 2025

(Left to Right: Gaby Bello, Carly Sullivan, Ashley Yu) The Mount Sinai group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.
Dr. Xiaoli Wang presents her ASH abstract “Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells”. View the abstract here!
Dr. Andrew Kuykendall presents his ASH abstract “A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1”. View the abstract here!

ASH Abstracts

Marina Kremyanskaya, MD,PhD

Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

Full ASH Abstract
John Crispino, PhD,MBA

Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms

Full Ash Abstract
John Mascarenhas, MD

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

Full ASH Abstract
Andrew Kuykendall, MD

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Full Ash Abstract
Min Lu, MD,PhD

Myelofibrosis stem cell fitness requires microenvironmental cell interactions

Full ASH Abstract
Xiaoli Wang, MD,PhD

Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

Full Ash Abstract
MD Babu Mia, PhD

Single cell transcriptional profiling reveals distinct subsets of human megakaryocytes in myelofibrosis

Full ASH Abstract